These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37682405)

  • 21. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
    Respir Med; 2021; 180():106311. PubMed ID: 33711782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
    Bensch GW; Prenner B; Berkowitz R; Galant S; Ramsdell J; Lutsky B
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):533-40. PubMed ID: 16680923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
    Kerwin E; Pascoe S; Bailes Z; Nathan R; Bernstein D; Dahl R; von Maltzahn R; Robbins K; Fowler A; Lee L
    Respir Res; 2020 Jun; 21(1):148. PubMed ID: 32532275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial.
    O'Byrne PM; Woodcock A; Bleecker ER; Bateman ED; Lötvall J; Forth R; Medley H; Jacques L; Busse WW
    Respir Res; 2014 Aug; 15(1):88. PubMed ID: 25108545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
    Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
    Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.
    Woodcock A; Bleecker ER; Busse WW; Lötvall J; Snowise NG; Frith L; Jacques L; Haumann B; Bateman ED
    Respir Res; 2011 Dec; 12(1):160. PubMed ID: 22188590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
    Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
    van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
    Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
    Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.